Vistagen Therap

Q1 FY2027 EarningsQ1 FY27 beat consensus across top and bottom-line metrics, with revenue of $1.48M significantly exceeding the $0.17M expectation due to a $1.2M one-time recognition from a licensing agreement. GAAP Net Loss of $13.0M was narrower than the anticipated $15.1M, and Diluted EPS of -$0.30 beat the consensus of -$0.36. While fasedienol missed its primary endpoint in the PALISADE-4 trial, positive post-hoc data in severe populations and a $31.7M cash position provide a bridge to late-2026/early-2027 operations.